Interim Chief Operating Officer
Rick Finnegan, has served as Interim Chief Operating Officer since September 2022. Mr. Finnegan previously worked at SAB Biotherapeutics (NASDAQ: SABS) as Chief Business Officer and Executive Vice President of Program Management from September 2018 to May 2022. Mr. Finnegan served as Senior Vice President of Operations and Program Management at rEVO Biologics from 2014 to 2018 and Executive Vice President of Global Strategic Accounts and Commercial Development at Syneos, (formerly inVentiv Health) from 2010 to 2013. Mr. Finnegan led the European Specialty Pharma division for Glenmark Pharmaceuticals where he was employed from 2008 to 2010. He served as Senior Vice President of Sales and Marketing from 2003 to 2006 for Critical Therapeutics and Vice President of New Product Marketing for Sanofi (formerly Genzyme). From 1989 to 2001 Mr Finnegan served in a range of U.S. and Global commercialization roles for Merck & Co. He holds a Bachelor of Science in Business Administration from the University of New Hampshire and a Master of Science in Management from Massachusetts Institute of Technology.